Ryan Spencer

CIK 1777938 · CEO and Director · last filed 2026-02-10

Ryan Spencer is a CEO and Director who has filed 25 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for DVAX, was dated Feb 10, 2026. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

25

Lifetime Open-Market Net

-$1.13M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted CEO and Director 136,000 $15.50 $2.11M -$1.13M 21 2026-02-10
Cidara Therapeutics, Inc. (CDTX) Delisted Director $221.38 $0 4 2026-01-07

Recent Filings

25 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2026-02-10 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Mixed −379,620 $0 EDGAR
2026-01-07 Cidara Therapeutics, Inc. (CDTX) Delisted Disp (D) $0 EDGAR
2025-12-29 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Mixed +118,415 -$2.13M EDGAR
2025-06-18 Cidara Therapeutics, Inc. (CDTX) Delisted Grant (A) $0 EDGAR
2025-02-20 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Mixed +18,472 -$472.3K EDGAR
2025-02-18 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Mixed +30,806 -$402.2K EDGAR
2025-02-12 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Mixed +9,624 -$148.0K EDGAR
2024-07-19 Cidara Therapeutics, Inc. (CDTX) Delisted Grant (A) $0 EDGAR
2024-04-30 Cidara Therapeutics, Inc. (CDTX) Delisted Grant (A) $0 EDGAR
2024-02-20 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Grant (A) +402 $3.8K EDGAR
Showing 110 of 25
Page 1 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.